Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
C. Phan, N. Bénéton, J. Delaunay, Z. Reguiaï, C. Boulard, Anne‐Claire Fougerousse, Élisa Cinotti, Marco Romanelli, L. Méry‐Bossard, D. Thomas‐Beaulieu, J. Parier, F. Maccari, Jean‐Luc Perrot, M. Ruer‐Mulard, Marie Bastien, É. Bégon, M. Samimi, C. Jacobzone, N. Quiles‐Tsimaratos, V. Descamps, M. Steff, P. Bilan, A. Vermersch‐Langlin, M. Kemula, E. Amazan, I. Kupfer‐Bessaguet, Anne-Caroline Cottencin, Francesca Prignano, Bulai Livideanu, J. Gottlieb, Alain Beauchet, E RESOPSO
Abstract
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n = 4), oral candidiasis (n = 3), and influenza-like illness (n = 3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ≥ 65 years.